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Abstract:  Chronic immune thrombocytopenic purpura (ITP) is generally a more benign 
disease than previously thought. Currently it is recommended that only those patients with 
severe and/or symptomatic thrombocytopenia definitely require treatment. Additional factors, 
such as age, lifestyle, and uremia can also influence the hemorrhagic risk and should be 
carefully assessed before decision-making on the appropriate management of patients with 
less severe forms of ITP. The recent introduction of new classes of therapeutic agents such as 
rituximab and the thrombopoietic growth factors has had a major impact on the management 
of ITP. Updated treatment guidelines have recently been made available but they are based 
largely on expert opinion rather than on high-quality clinical trial evidence. This structured 
review is focused on the management of adults with chronic ITP, including the use of new 
classes of agents.
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Introduction
According to the recent international consensus report,1 primary immune 
  thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by 
isolated thrombocytopenia, defined as a platelet count ,100 × 109/L, and the absence 
of any obvious initiating and/or underlying cause for thrombocytopenia. It can be 
classified by duration into newly diagnosed, persistent (3–12 month duration), and 
chronic ($1 year duration).
The pathogenic mechanism of thrombocytopenia in ITP was classically interpreted 
as increased platelet destruction mediated by autoantibodies. However, today it is well 
known that more complex mechanisms are involved including both impaired platelet 
production and T-cell-mediated effects.2–6
The natural history of untreated ITP shows differences between adults and children. 
Typically, ITP in adults exhibits an insidious onset and normally follows a chronic 
course,7 whereas in children it is usually preceded by a viral infection and more than 
60% of patients spontaneously achieve normal platelet counts within 6 months. A survey 
by the Intercontinental Childhood ITP Study Group (ICIS-1)8 involving more than 2,000 
children showed a peak age of 1–5 years, platelet counts at presentation ,20 × 109/L, 
and slightly more in boys (55%) than girls. Initial treatment of children with glucocor-
ticoids, intravenous immune globulin (IVIG) or anti-D   immunoglobulin (anti-D) may 
cause a more rapid increase of the platelet count compared with no therapy.9 However, 
it is not well established whether an early therapeutic intervention decreases morbidity 
from bleeding or increases complete remission rates.10International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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ITP during pregnancy have particular management needs 
closer to those of patients who develop acute thrombocytope-
nia and are outside the scope of the present review.
Spontaneous remissions occur rarely in adults. In   general, 
adults with severe symptomatic thrombocytopenia are 
given treatment, most often with glucocorticoids. However, 
most patients do not maintain normal platelet counts after 
  glucocorticoids are stopped.7–12
In general, ITP in adults is more prevalent in women 
(30–60 years).9,13 Signs and symptoms vary widely. Many 
patients have either no symptoms or minimal bruising, while 
others experience serious bleeding episodes that may include 
gastrointestinal (GI) bleeding, extensive skin and mucosal 
hemorrhage or intracranial hemorrhage (ICH). The severity 
of thrombocytopenia correlates to some extent with   bleeding 
risk.13,14 Additional factors including age, lifestyle, and 
uremia can also influence the risk and should be carefully 
assessed before making a decision about the appropriate 
management. On the other hand, adults presenting with mild 
and asymptomatic thrombocytopenia, with platelet counts 
between 30 × 109/L and 50 × 109/L, seem to have a stable 
and benign course without treatment.7,13,15,16 Data from case 
series suggest that fewer than 20% of such patients eventually 
develop more severe thrombocytopenia and require treatment 
after 3–7 years of follow-up.7
Results from some long-term follow-up series suggest 
that ITP is a more benign disease than previously thought, 
and should be treated by a conservative approach, reserving 
aggressive treatment for patients with severe and symptom-
atic thrombocytopenia.7,13,16 The most relevant information 
from these series is: (i) most patients (42%) have a platelet 
count .50 × 109/L and remain untreated; (ii) the spontaneous 
remission rate is 9%; and (iii) patients with a platelet count 
,50 × 109/L had a good outcome, with only 12% present-
ing with frank bleeding, while 28% were asymptomatic, 
19% did not need specific treatment, and 55% needed only 
first-line treatment.
Mortality attributable to thrombocytopenia is low 
(1%–4%), usually caused by severe bleeding and, more 
importantly, infections associated with   immunosuppressive 
therapy. Splenectomy is associated with postoperative 
  complications and may result in significant morbidity and 
costs derived from prolonged hospitalization or readmission 
in a sizable proportion of patients that has been reported up 
to 26%.16
In this article we will review the long-term management 
of chronic ITP in adults, including the role of rituximab and 
the new thrombopoietic growth factors.
Treatment strategies
General therapeutic principles
Because severe bleeding is rare in patients with ITP and 
normally occurs when platelet counts are ,10,000/µL,17 
the main goal of therapy is to maintain a safe platelet count 
(not necessarily a normal count) to prevent major bleeding, 
while withholding drugs, when possible, to avoid adverse 
effects of therapy that often exceed any problems caused 
by the ITP.1 Keeping these criteria in mind, patients with 
mild, asymptomatic thrombocytopenia should not be treated 
unless they have a risky lifestyle (sports etc)18 or they 
are at risk for bleeding because of associated conditions 
  (hypertension,   cerebrovascular disease),15,19 have disorders 
requiring   treatment with anticoagulant or antiplatelet agents, 
or a need for surgery or other invasive procedures. If patients 
have moderate or severe thrombocytopenia and bleeding 
symptoms, treatment must be started but should be limited in 
duration unless symptomatic thrombocytopenia persists.
The treatment decision-making in ITP should be shared 
between the clinician and the patient. As has been repeatedly 
emphasized, for some patients, the morbidity associated with 
side effects of therapy may exceed any problem caused by the 
ITP. Patients with life-threatening bleeding require immediate 
intervention. This situation is uncommon but more frequent 
in elderly patients (10%–13%).7,15,19,20 Platelet transfusion is 
usually accepted as the initial therapy because it can provide 
critical temporary support,   maintaining platelet counts above 
20 × 109/L in a number of cases (42%).21,22 Transfusions must 
be combined with IVIG (1 g/kg, repeated the following day if 
the platelet count remains ,50 × 109/L) and with intravenous 
pulse methylprednisolone (1 g, repeated daily for 3 doses). 
If previous treatments fail, intravenous recombinant human 
factor VII can be successfully used.23–25
First-line treatment
Accurate initial diagnosis of ITP is necessary because some 
adults may have a self-limited thrombocytopenia caused 
by an infection or an adverse drug effect.13 Thus, treatment 
of concurrent infections or withdrawal of the implicated drug 
must be considered in the initial phases of ITP management. 
Among the acute and chronic bacterial and viral infections that 
have been associated with thrombocytopenia, the   following 
microorganisms must be considered: hepatitis C virus, human 
immunodeficiency virus, cytomegalovirus, Epstein–Barr virus, 
parvovirus, and Helicobacter pylori.26 In these cases, treatment 
of concomitant infection may improve the thrombocytopenia 
and steroids or   immunosuppressive agents should be avoided 
because they may worsen the infection.27,28International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Since spontaneous remissions are uncommon in 
adults with ITP, the administration of glucocorticoids is 
the   recommended treatment when necessary. Prednisone 
(1 mg/kg per day orally) or high-dose dexamethasone 
(HDD), 40 mg/day orally for 4 days, repeated every 
14–28 days as needed, are the regimens most commonly 
used. However, only 20% of patients receiving prednisone 
as first-line   treatment have a sustained complete remission 
lasting more than six months after maintenance therapy is 
discontinued.7 The role of HDD in first-line treatment of 
ITP in adults is well known.12,29,30 The best results with HDD 
are 85% initial response and, among responders, 50% will 
have a sustained response for up to 2 years. Advantages of 
this regimen are the short and defined duration of treatment 
compared with the more prolonged duration of daily oral 
prednisone treatment.31
Second-line treatment and management  
of refractory ITP
In case of glucocorticoid treatment failure (refractoriness or 
early relapse following withdrawal), a second-line treatment 
can be given when necessary. Treatment choice includes 
IVIG, anti-D in RhD-positive individuals (both can be 
used as a first option and classified as first-line treatment), 
  splenectomy, and immunosuppressive drugs, including 
rituximab. Splenectomy remains the most effective option, 
with the highest rate of durable complete remissions,32 and 
provides long-lasting responses for the majority of cases. 
However, there are no randomized studies that give guid-
ance on the most convenient order of using these distinct 
alternatives that will be discussed below.
Splenectomy
The decision to perform a splenectomy should take into 
account both the severity of bleeding and   thrombocytopenia, 
as well as the risk of major bleeding. Splenectomy may 
not be appropriate for patients with mild or moderate 
  thrombocytopenia and minor bleeding, except for patients 
with a lifestyle estimated to be at high risk for bleeding (police 
officers, firefighters, sports, high probability of   accidents). 
The indication for splenectomy must be deferred until fail-
ure of first-line treatment for ITP is well documented and 
spontaneous recovery is judged to be unlikely. If necessary, 
splenectomy can be performed 4–6 weeks after diagnosis of 
treatment failure.1 If rituximab is used as a therapeutic alter-
native before splenectomy, the response should be evaluated 
after a minimum follow-up because responses can occur up 
to 6–8 weeks later.60
The effectiveness of splenectomy is well known, and 
the main case series reported (not controlled studies, with 
  heterogeneous patients and different follow-up)33,34 have 
comparable results: approximately two-thirds of patients 
recovered to a normal platelet count that persisted for the 
duration of observation.31,32,35 In 14 case series reporting 
only adults, 456 (64%) of 707 patients had a complete 
response with a median follow-up of 7.25 years (range, 
5–12.75 years).32 There is a lack of reliable tools to accu-
rately predict the response of ITP to splenectomy. In gen-
eral, younger patients respond better,32,33,36,37 but a specific 
age cutoff for this observation has not been determined. 
Splenectomy is considered a low-risk surgical procedure, 
especially in   previously healthy patients, but it must be 
performed by expert surgeons. Patients should be prepared 
to have a platelet count .50 × 109/L before surgery, usually 
by giving a course of glucocorticoids, IVIG, anti-D, and/or 
platelet   transfusions. Today, with the extent of laparoscopic 
techniques, the expected morbidity (9.6%) and mortality 
(0.2%) have dramatically decreased.32,38–41
Because splenectomy may predispose to fatal   infections 
by encapsulated bacteria (estimated mortality of 0.73 per 
1,000 patient years),42 a consensus has been reached to 
recommend vaccination against Streptococcus pneumoniae 
(polyvalent vaccine), Hemophilus influenzae b, and   Neisseria 
meningitides (conjugate vaccine).1 Vaccination must be done 
at least 4 weeks prior to splenectomy or alternatively 2 weeks 
after this surgical procedure.81 It should be noted that vac-
cines may not be effective in patients treated with rituximab 
within the previous 6 months.81
Approximately 20% of patients relapse after splenectomy 
and exhibit severe ITP or have a risk of bleeding that requires 
additional therapy. In these refractory ITP patients, apart from 
reconsidering other potential causes of   thrombocytopenia, 
the development of accessory spleens should be ruled 
out. The management of refractory ITP is a challenge and 
several therapeutic options can be considered. In addition, 
some refractory patients not meeting the criteria for severe 
ITP can face clinical situations with increased risk of bleed-
ing, such as surgery, bucco-dental interventions or trauma 
in which there is a need for a rapid and temporary response. 
Corticosteroids, IVIG or thrombopoietic growth factors 
(see below) can be useful in these situations.
Corticosteroids
Both low-dose (prednisone 5–10 mg/day) and high-dose 
  corticosteroids in brief courses have been used to maintain 
a safe platelet count in refractory patients. Experiences have International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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been disappointing with failure to achieve   complete   remissions, 
short response times, and/or increased toxicity.43–46
IvIG and anti-D
Both agents increase the platelet count within several days 
in most patients with ITP, with an effect that may last for 
several weeks.10,36,47 However, neither modality is expected 
to induce a long-term remission. Nevertheless, these agents 
may be valuable in patients with life-threatening bleeding or 
prior to splenectomy or other surgical procedures.
Immunosuppressive drugs and miscellaneous agents
Several single agents have been used with marginal efficacy. 
Azathioprine,48 cyclosporin A,49,50 and cyclophosphamide51,52 
are immunosuppressive drugs that have been used after 
  treatment failure in both splenectomized and nonsplenecto-
mized patients. Complete response rates vary from 24% to 
85%, but their use is limited because of the development of 
serious adverse effects such as infections, secondary tumors, 
hypertension or renal insufficiency. The list of drugs used in 
ITP also includes danazol,53 dapsone,54,55 or mycophenolate 
mofetil56,57 all with poorly defined efficacy. Interestingly, a 
recent retrospective, observational study reported encourag-
ing results using a combination of azathioprine, mycopheno-
late mofetil, and cyclosporine in a relatively small series of 
patients with particularly severe and refractory ITP.58
Rituximab
This monoclonal antibody is being increasingly used 
  off-label for refractory chronic ITP. Our main knowledge 
about efficacy and safety of this agent in this setting comes 
from a systematic review59 and a prospective multicenter 
phase II trial involving 60 patients treated with 4 weekly 
intravenous injections of rituximab (375 mg/m2 per dose).60 
Three important conclusions can be made: (i) rituximab 
achieved sustained platelet counts ($30 × 109/L) in 40% 
of patients; (ii) rituximab was discontinued because of side 
effects in only 1 patient; and (iii) in nonresponders, a good 
response was obtained in 60% of patients by splenectomy. 
Although the most used dose of rituximab in ITP patients 
is 375 mg/m2/week for 4 weeks, the standard dose is not 
yet established. It seems that lower doses (100 mg/m2/week 
for 4 weeks) could be useful to achieve responses and 
minimize adverse effects. High response rates have been also 
reported recently with rituximab combined with high dose 
dexamethasone.61 Although we must be cautious with these 
results, it seems that rituximab can be used without com-
promising the response to splenectomy in case of   rituximab 
failure.60 Nevertheless, since some cases of progressive 
multifocal   leukoencephalopathy have been reported after 
rituximab treatment in patients with lymphoproliferative or 
  autoimmune disorders, additional long-term safety data are 
required before recommending the widespread use of this 
monoclonal antibody in refractory chronic ITP.62
Antifibrinolytics
In patients with severe bleeding in spite of other treatments 
and supportive measures, the use of antifibrinolytic agents 
such as oral or intravenous tranexamic acid or aminocaproic 
acid may be an appropriate adjunct measure.63
Chemotherapy
Vinca alkaloids as single agents,64,65 or several   combinations 
of different doses of cyclophosphamide, prednisone, 
  vincristine, etoposide, and azathioprine have been used in 
patients with refractory ITP and have achieved complete 
responses in 42% of patients.66–67
Hematopoietic stem cell transplantation
Although toxicities associated with stem cell   transplantation 
are potentially fatal, both autologous and allogeneic 
transplantation have been used in refractory ITP patients. 
  Remissions have been reported but very few have been 
durable.69–72 Clearly this approach must be reserved for 
patients with refractory ITP with severe bleeding complica-
tions unresponsive to other modalities.
Other treatments
Some miscellaneous treatments historically used are no   longer 
justified because of their demonstrated lack of   efficacy or 
excessive toxicity, including vitamin C,   colchicine, interferon, 
ex vivo perfusion of plasma using protein A immunoadsorption 
columns or plasmapheresis as an isolated approach.
New thrombopoietic growth factors
A better understanding of ITP pathogenesis has lead to 
the development of a novel nonimmunologic therapeutic 
approach by stimulating platelet production. Several types 
of thrombopoiesis-stimulating agents (eg, thrombopoietin 
(TPO) receptor agonists), including recombinant TPOs 
(which are no longer available), peptide TPO mimetics 
such as romiplostim, and nonpeptide TPO mimetics such 
as eltrombopag, have been developed in recent years. Both 
romiplostim and eltrombopag have been recently approved 
for clinical use in patients with chronic ITP refractory to 
corticosteroids, immunoglobulins, or splenectomy.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Romiplostim consists of an IgG1 Fc component linked 
to a peptide domain with 4 binding sites for Mpl, the TPO 
receptor.71,72
With this structure, the development of antibodies to 
  romiplostim or to endogenous TPO, as it was previously 
observed with the recombinant TPO polyethylene glycol-
conjugated human megakaryocyte growth and   development 
factor (PEG-MGDF), is unlikely. Based on 2 Phase I/II trials,74,75 
a parallel placebo-controlled Phase III trial,76 and an open-label 
study,77 the most important   observations regarding the use of 
romiplostim are the following: (i) romiplostim produces a 
durable platelet response in both previously splenectomized 
(38%) and nonsplenectomized patients (56%); (ii) adult 
patients responding to romiplostim experience an improve-
ment of health-related quality of life;78 (iii) side effects are 
very unusual, mild to moderate headache being the most 
frequent (39%), although transient worsening of thrombocy-
topenia during the post-treatment period (vaginal hemorrhage) 
and deep venous thrombosis owing to secondary thrombocy-
tosis have been occasionally reported; (iv) antibodies against 
endogenous TPO or romiplostim have not been reported.
Similarly, a Phase II dose-ranging trial79 and a random-
ized (2:1 drug to placebo), double-blind, placebo-controlled 
Phase III trial80 have provided the following information about 
the use of eltrombopag, which is a TPO nonpeptide mimetic: 
(i) toxicities and adverse effects of eltrombopag are low and 
similar to placebo, while patients receiving 50–75 mg/day 
show a trend toward fewer bleeding events on therapy; 
(ii) eltrombopag achieves a platelet count .50 × 109/L at 
6 weeks in 59% of splenectomized and nonsplenectomized 
patients, and platelet counts return to baseline within 2 weeks 
of the end of treatment; (iii) liver function test abnormalities 
are present in 13% of patients treated with eltrombopag.
Although most reported adverse effects with both 
  thrombopoietic agents were mild, concerns have been raised 
over the increased bone marrow reticulin occasionally 
found in patients treated with romiplostim or eltrombopag. 
Because the clinical meaning of this observation is not well 
  understood, subsequent long-term clinical trials will address 
the importance of this finding and whether routine   monitoring 
is required.
Romiplostim is administered subcutaneously once weekly 
and the dose ranges from 1 to 10 µg/kg, whereas eltrombopag is 
orally administered in doses ranging from 25 to 75 mg daily. Dos-
ages are chosen in order to achieve platelet counts $50 × 109/L, 
considered the optimal threshold to reduce the risk for bleeding. 
Experience with these drugs is limited but, because of their 
mechanism of action, both are effective as long as they are 
maintained and they might be useful for temporary therapy 
when remission with other treatments is expected to be delayed 
or when a splenectomy is postponed.
Algorithm for the management  
of ITP
Conclusions and future research 
directions
Although it was first described more than two centuries ago, 
progress in our understanding of the main aspects of ITP 
has only become significant in the last few years. However, 
the diagnosis of ITP continues to be one of exclusion, the 
first-line treatment (glucocorticoids) has been the same 
for more than 60 years, and the most effective second-line 
therapy continues to be splenectomy. Moreover, very limited 
knowledge has been obtained from the few randomized and 
controlled clinical trials conducted.
Nevertheless, some advances that have been relevant 
in recent years and that could change the paradigm of ITP 
management are:
•	 The introduction of rituximab as second-line treatment 
(before performing splenectomy), which is an interesting 
option to avoid or postpone splenectomy in patients with 
increased surgical risk.
•	 The new understanding that the pathophysiology of ITP is 
based not only on the destruction of platelets but on their 
impaired production in the bone marrow, which gives impe-
tus to the use of the thrombopoiesis-stimulating agents romi-
plostim or eltrombopag. These agents have demonstrated 
their efficacy in controlling disease in both splenectomized 
and nonsplenectomized patients, with few adverse effects.
Finally, as the investigation of ITP has for years been 
mainly based on noncontrolled studies, recent efforts 
to achieve an international consensus on terminology, 
  investigation, and management of patients with ITP is to be 
considered as an attempt to overcome the difficulties of the 
past and encourage future research focused on randomized 
trials and large multicenter prospective cohort studies.79
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